In vitro assessment of the anticancer activity of quinaldic acid against human breast cancer cells (MCF-7)
Paper Details
In vitro assessment of the anticancer activity of quinaldic acid against human breast cancer cells (MCF-7)
Abstract
Breast carcinoma represents one of the most frequently diagnosed types of cancer among women throughout the world. The drawbacks of current chemotherapy drugs include adverse side effects, development of drug resistance and lack of selectivity for cancer cells. This highlights the need to develop novel, highly active antitumor compounds with improved therapeutic efficacy and safety. Quinaldic acid (QA) is a biologically active compound that has shown antiproliferative activity in some cancer models, but its anticancer activity against breast carcinoma has not been sufficiently investigated. The present research aims to study the anticancer activity of QA in MCF-7 cells (human breast adenocarcinoma cells). Antiproliferative activity was determined with the MTT assay, with cisplatin used as the standard drug. The generation of reactive oxygen species (ROS), polarization of mitochondrial membrane and nuclear morphology were studied to evaluate the possible mechanisms of action of QA. The apoptosis inducing potential and quantitative estimation of apoptotic cells were identified with AO/EtBr staining and flow cytometry respectively. QA showed dose-dependent antiproliferative activity against MCF-7 cells along with considerably lower cytotoxicity in normal L929 cells, which indicates its higher cytotoxicity against carcinoma cells. The QA treatment resulted in a significant increase in ROS production and depolarization of the mitochondrial membrane, which highlights the effective role of the intrinsic apoptosis pathway. DAPI and AO/EtBr staining revealed prominent apoptotic features and a higher percentage of apoptotic cells. Flow cytometry viable cell count reduction and an increase in early and late apoptotic cell counts. QA showed greatest and selective anticancer activity against MCF-7 by inducing ROS-mediated mitochondrial dysfunction and apoptosis, while exhibiting comparatively low cytotoxicity toward normal fibroblast cells.
Abdulkareem IH. 2013. Aetio-pathogenesis of breast cancer. Nigerian Medical Journal 54(6), 371-375.
Aghamir F, Moradi Alvand Z, Jalali N, Eghlima G. 2026. Oxidative stress-associated mitochondrial dysfunction and apoptotic gene modulation induced by Drimia maritima-mediated Ag₂S quantum dots in human HL-60 leukemia cells. Advanced Redox Research 20, 100181.
Akter S, Madhuvilakku R, Kar AK, Nila IS, Liu P, Inuzuka H, Wei W, Hong Y. 2026. Reactive oxygen species (ROS) in cancer: From mechanism to therapeutic implications. Signal transduction and targeted therapy. 11(1):111.
Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. 2022. Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast. 66:15-23.
Asma ST, Acaroz U, Imre K, Morar A, Shah SRA, Hussain SZ, Arslan-Acaroz D, Demirbas H, Hajrulai-Musliu Z, Istanbullugil FR, Soleimanzadeh A, Morozov D, Zhu K, Herman V, Ayad A, Athanassiou C, Ince S. 2022. Natural products/bioactive compounds as a source of anticancer drugs. Cancers 14(24), 6203.
Balch CM, Liao N, Lam DS, Weitzel JN, Xu RH, Attard G, Bunn PA, Eggermont AM, He J, Kitagawa Y, Lim ST. 2026. The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection. Ecancermedicalscience. 20, 2071.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. 2024. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 74(3), 229-263.
Burguin A, Diorio C, Durocher F. 2021. Breast cancer treatments: Updates and new challenges. Journal of Personalized Medicine 11(8), 808.
Chaudhari R, Patel V, Kumar A. 2024. Cutting-edge approaches for targeted drug delivery in breast cancer: Beyond conventional therapies. Nanoscale Advances 6(9), 2270-2286.
Dong R, Wang J, Guan R, Sun J, Jin P, Shen J. 2025. Role of oxidative stress in the occurrence, development, and treatment of breast cancer. Antioxidants 14(1), 104.
Dos Anjos GR, Machado GF, de Barros CP, de Andrade VP, Maciel RM, Cunha LL. 2025. Cancer survivorship in low-and middle-income countries: challenges, needs, and emerging support strategies. Frontiers in Public Health. 13,1601483.
Freihat O, Sipos D, Kovacs A. 2025. Global burden and projections of breast cancer incidence and mortality to 2050: A comprehensive analysis of GLOBOCAN data. Frontiers in Public Health 13, 1622954.
Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, Mutebi M, Garvey G, Soerjomataram I, Fidler-Benaoudia MM. 2025. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nature medicine. 31(4), 1154-62.
Langner E, Walczak K, Jeleniewicz W, Turski WA, Rajtar G. 2015. QA inhibits proliferation of colon cancer HT-29 cells in vitro: Effects on signaling pathways. European Journal of Pharmacology 757, 21-27.
Liu S, Liu J, Wang Y, Deng F, Deng Z. 2025. Oxidative stress: Signaling pathways, biological functions and disease. MedComm 6(7), e70268.
Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. 2021. Breast cancer: Epidemiology, risk factors, classification, prognostic markers and current treatment strategies- An updated review. Cancers 13(17), 4287.
Ly JD, Grubb DR, Lawen A. 2003. The mitochondrial membrane potential (Δψm) in apoptosis: An update. Apoptosis 8(2), 115-128.
Moten A, Schafer D, Farmer P, Kim J, Ferrari M. 2014. Redefining global health priorities: Improving cancer care in developing settings. Journal of Global Health 4(1), 010304.
Nikiforova AB. 2026. On the edge of benefit and harm: Reactive oxygen species in cancer. International Journal of Molecular Sciences 27(15), 6887.
Ryspayeva D, Seyhan AA, MacDonald WJ, Purcell C, Roady TJ, Ghandali M, Verovkina N, El-Deiry WS, Taylor MS, Graff SL. 2025. Signaling pathway dysregulation in breast cancer. Oncotarget 16, 168-201.
Tamilarasi S, Kamali T, Sivasankaran SM, Deepa B. 2026. Pharmacological properties of quinaldic acid: A concise review. European Journal of Biomedical 13(6), 066-070.
Wang X, Zhang H, Chen X. 2019. Drug resistance and combating drug resistance in cancer. Cancer Drug Resistance 2(2), 141-160.
Wilkinson L, Gathani T. 2022. Understanding breast cancer as a global health concern. British Journal of Radiology 95(1130), 20211033.
Wu W, He Y, Zhang C. 2026. Emerging targeted and multimodal therapeutic strategies in breast cancer: A comprehensive review. Breast Cancer 18, 575936.
N. Medhavi, S. M. Sivasankaran, K. Selvakumar, K. Harish, S. Manoharan*, 2026. In vitro assessment of the anticancer activity of quinaldic acid against human breast cancer cells (MCF-7). Int. J. Biosci., 29(3), 1-10.
Copyright © 2026 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.